Anthrogen
AI‑driven protein design platform that creates and validates novel biologics at atomic scale.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑driven protein design platform that creates and validates novel biologics at atomic scale.
Protein therapeuticsEnzyme engineering
Technology Platform
Odyssey is a 102‑billion‑parameter protein language model integrated with massively parallel experimental validation, enabling multi‑objective design of novel proteins at atomic scale.
Opportunities
Leveraging its AI‑experimental loop, Anthrogen can accelerate protein therapeutics pipelines for pharma partners and expand into industrial enzyme markets.
Risk Factors
Technical risk in scaling high‑throughput validation and demonstrating clinically relevant candidates; competitive pressure from larger AI‑biotech firms.
Competitive Landscape
Competes with AI‑driven protein design firms like Insilico Medicine and structural prediction leaders such as DeepMind, but differentiates through its integrated experimental verification pipeline.